Company: ZLAB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038548
Chunk: 32

Company: Zai Lab Ltd
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 32
---
)(0.14)Weighted-average shares used in calculating net loss per ordinary share - basic and diluted 1,091,933,150 975,937,790 1,086,413,130 974,541,780 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

3

Zai Lab Limited 

Unaudited Condensed Consolidated Statements of Comprehensive Loss 

(in thousands of $) 

Three Months Ended June 30,Six Months Ended June 30,2025202420252024Net loss(40,727)(80,277)(89,165)(133,748)Other comprehensive (loss) income, net of tax of nil:Foreign currency translation adjustments(2,955)3,605 (4,167)5,147 Comprehensive loss(43,682)(76,672)(93,332)(128,601)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

4

Zai Lab Limited 

Unaudited Condensed Consolidated Statements of Shareholders’ Equity 

(in thousands of $, except for number of shares) 

Ordinary SharesAdditionalpaidin capitalAccumulateddeficitAccumulatedothercomprehensiveincomeTreasury StockTotalNumberofSharesAmountSharesAmountBalance at December 31, 20241,082,614,740 7 3,264,295 (2,453,083)50,515 (4,912,200)(20,836)840,898 Issuance of ordinary shares upon vesting of restricted shares137,540 00— — — — — Exercise of share options6,324,120 03,733 — — — — 3,733 Issuance cost of the follow-on public offering— — (28)— — — — (28)Share-based compensation— — 15,800 — — — — 15,800 Net loss— — — (48,438)— — — (48,438)Foreign currency translation— — — — (1,212)— — (1,212)Balance at March 31, 20251,089,076,400 7 3,283,800 (2,501,521)49,303 (4,912,200)(20,